Please login to the form below

Not currently logged in
Email:
Password:

After Senate vote, Cures Act is en route to Obama for signature

Set to accelerate access to new therapies through real-world data and surrogate efficiency measures
US flag

Legislation designed to make new therapies accessible to patients more quickly has been passed by the US Senate, with just a signature by President Obama now required before it comes into law.

The US Senate voted 94 to 5 to approve the 21st Century Cures Act, a wide-ranging and controversial bill that will shake up the operations of the FDA and lead to the introduction of new mechanisms to speed the approval of new pharmaceuticals and medical devices.

As examples, it could allow a drug that has been approved in one indication a truncated approval route for a second, greater reliance on surrogate rather than clinical efficacy measures in trials, and the adoption of new forms of evidence for efficacy such as real-world data.

From those changes stem the controversy, with critics of the bill - including consumer group Public Citizen - arguing that it panders to the pharma industry and lowers the bar for proving safety and efficacy before new medicines can reach the market. There are also concerns about a new accelerated approval pathway for regenerative medicines such as stem cell therapies.

The agency gets an extra $500m over the coming five years to help fund the changes and the Act also commits funding to three major projects introduced under Pres Obama's administration - the Precision Medicine Initiative, Cancer Moonshot and the BRAIN Initiative seeking treatments for diseases such as dementia and epilepsy as well as traumatic brain injury.

In his weekly address, President Obama said the new bill is "an opportunity to save lives, and an opportunity we just can't miss", adding: "I'll sign it as soon as it reaches my desk."

The Biotechnology Innovation Organization (BIO), which represents biotech companies, welcomed the news, saying the new act "takes important steps towards placing patients at the centre of the drug development process".

BIO said it establishes "a framework for incorporating patient views into the development and regulatory review process in a more structured and transparent way, both with respect to patient input for benefit-risk assessments and use of patient experience in data in regulatory decision-making."

Article by
Phil Taylor

8th December 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....